- Home
- Publications
- Publication Search
- Publication Details
Title
Current State of Immunotherapy for Treatment of Glioblastoma
Authors
Keywords
Glioblastoma, Immunotherapy, Vaccine, CAR-T, Checkpoint inhibitors
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 3, Pages -
Publisher
Springer Nature
Online
2019-02-21
DOI
10.1007/s11864-019-0619-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma
- (2018) John A. Barrett et al. CANCER GENE THERAPY
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
- (2018) Linda M. Liau et al. Journal of Translational Medicine
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Current state of immunotherapy for glioblastoma
- (2018) Michael Lim et al. Nature Reviews Clinical Oncology
- Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC
- (2018) Timothy F Cloughesy et al. NEURO-ONCOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature
- (2018) Markus Leitinger et al. Frontiers in Immunology
- Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine.
- (2018) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
- (2018) Pakawat Chongsathidkiet et al. NATURE MEDICINE
- Viruses in cancer therapy — from benchwarmers to quarterbacks
- (2018) Pierpaolo Peruzzi et al. Nature Reviews Clinical Oncology
- ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE
- (2018) David Peereboom et al. NEURO-ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Optimizing bevacizumab dosing in glioblastoma: less is more
- (2017) Abdulrazag Ajlan et al. JOURNAL OF NEURO-ONCOLOGY
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies
- (2017) David Chen et al. Translational Research
- Chimeric antigen receptor T-cell therapy for glioblastoma
- (2017) Analiz Rodriguez et al. Translational Research
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination
- (2017) Phillip M. Galbo et al. Oncotarget
- History and current state of immunotherapy in glioma and brain metastasis
- (2017) Tresa McGranahan et al. Therapeutic Advances in Medical Oncology
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
- (2017) Samantha N. Reiss et al. Journal for ImmunoTherapy of Cancer
- Corticosteroids compromise survival in glioblastoma
- (2016) Kenneth L. Pitter et al. BRAIN
- Advances and challenges: dendritic cell vaccination strategies for glioblastoma
- (2016) Teilo H. Schaller et al. Expert Review of Vaccines
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
- (2015) Hideho Okada et al. LANCET ONCOLOGY
- Prospects of immune checkpoint modulators in the treatment of glioblastoma
- (2015) Matthias Preusser et al. Nature Reviews Neurology
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
- (2014) B. Thaci et al. NEURO-ONCOLOGY
- A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool
- (2014) Lorea Manterola et al. NEURO-ONCOLOGY
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
- (2013) Michael Weller et al. INTERNATIONAL JOURNAL OF CANCER
- Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
- (2013) Manfred Westphal et al. LANCET ONCOLOGY
- Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
- (2013) Orin Bloch et al. NEURO-ONCOLOGY
- Stem-like Tumor-Initiating Cells Isolated from IL13R 2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine-Redirected T Cells
- (2012) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
- (2012) Brendan Fong et al. PLoS One
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
- (2010) N. Ahmed et al. CLINICAL CANCER RESEARCH
- Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
- (2010) Hideho Okada et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More